Table 1_Evaluation of the efficacy as well as prognosis of targeted therapy for advanced non-small cell lung cancer patients with different expression of miR-183 family in body fluids.docx

AimTo explore the relationship between the expression of miR-183 family in body fluids and the treatment effect and prognosis of advanced non-small cell lung cancer (NSCLC) patients received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
MethodsOne hundred and fifty advanced NSCLC patients were selected as the study subjects, all of whom received EGFR-TKI osimertinib. The efficacy of all NSCLC patients was evaluated after 2 courses of treatment, and the patients were allocated into effective group (n = 40) and ineffective group (n = 110). Real-time fluorescence quantitative PCR detected the relative expression of serum miR-183 in both groups. The EGFR-TKI efficacy of NSCLC patients with different clinical characteristics along with the survival rate of patients with different serum miR-183 relative expression levels before treatment was compared. Multivariate Cox regression model was implemented to analyze the factors affecting survival of NSCLC patients after EGFR-TKI treatment.
ResultsAfter treatment, serum miR-183 expression in effective group was declined relative to before treatment and ineffective group, and serum miR-183 expression in ineffective group was elevated compared to before treatment (all P < 0.05). The EGFR-TKI efficacy of NSCLC patients with no smoking history and miR-183 relative expression level <1.77 before treatment was better than that of NSCLC patients with smoking history and miR-183 relative expression level ≥1.77 before treatment (all P < 0.05). The 2-years survival rate in patients with miR-183 relative expression level <1.77 before treatment was elevated compared to that in patients with miR-183 relative expression level ≥1.77 before treatment (all P < 0.05). The relative expression of miR-183 before treatment was an independent influencing factor for survival of NSCLC patients after EGFR-TKI treatment (both P < 0.05).
ConclusionThe low serum miR-183 expression before treatment is closely linked to the efficacy along with prognosis of advanced NSCLC patients received EGFR-TKI therapy. Monitoring the level of serum miR-183 may be helpful to evaluate the prognosis of NSCLC patients.